Direct Binding of a Hepatitis C Virus Inhibitor to the Viral Capsid Protein

Over 130 million people are infected chronically with hepatitis C virus (HCV), which, together with HBV, is the leading cause of liver disease. Novel small molecule inhibitors of Hepatitis C virus (HCV) are needed to complement or replace current treatments based on pegylated interferon and ribaviri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kota, Smitha, Takahashi, Virginia, Ni, Feng, Snyder, John K., Strosberg, A. Donny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289641/
https://www.ncbi.nlm.nih.gov/pubmed/22389688
http://dx.doi.org/10.1371/journal.pone.0032207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289641/
https://www.ncbi.nlm.nih.gov/pubmed/22389688
http://dx.doi.org/10.1371/journal.pone.0032207

Ejemplares similares